CG Oncology (CGON) shares have been reacting to fresh clinical data, after the company reported early CORE-008 Phase 2 results for cretostimogene grenadenorepvec plus gemcitabine in high-risk non muscle invasive bladder cancer.

The recent CORE-008 data release has arrived after a strong run, with CG Oncology’s year to date share price return of 53.74% and a very large 1 year total shareholder return of 151.76%. This suggests that optimism around cretostimogene’s progress is still feeding into sentiment despite some shorter term consolidation.

If you are looking beyond a single biotech story, this could be a helpful moment to scan for other healthcare companies using artificial intelligence and see what stands out in our 34 healthcare AI stocks

With the stock up 53.7% year to date and trading at a sizeable discount to the average analyst price target, the key question now is whether CG Oncology is still undervalued or if the market is already pricing in future growth.

Preferred Price to Book of 5.2x: Is it justified?

On value checks, CG Oncology screens differently depending on what it is compared to, with the stock trading at a P/B ratio of 5.2x.

The P/B ratio compares the company’s market value to its net assets on the balance sheet. This can be a useful reference point for early stage biopharma stocks that are not yet profitable. For CG Oncology, this lens highlights how much investors are currently willing to pay relative to the company’s book value.

Versus peers, the picture is mixed. CG Oncology’s P/B of 5.2x is described as good value against a peer average of 11.6x. However, it is considered expensive against the broader US Biotechs industry average of 2.5x. This suggests investors are assigning a higher valuation multiple than the sector in aggregate but not the highest within its closer peer set.

Result: Price-to-book of 5.2x (ABOUT RIGHT)

However, you also need to weigh the risk that clinical trial outcomes or regulatory reviews do not align with current expectations, especially given CG Oncology’s US$186.7 million net loss.

Another View: What Does The SWS DCF Model Say?

The SWS DCF model paints a very different picture compared to the 5.2x P/B ratio. With CG Oncology at $64.25 and the DCF fair value estimate at $383.01, the stock is described as trading 83.2% below that fair value. For you, that gap raises a simple question: is this a margin of safety or a sign that expectations are running ahead of reality?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CG Oncology for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 48 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment clearly split between strong upside signals and clear risks, it makes sense to look at the numbers yourself and decide quickly where you stand. A useful place to start is the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If you only focus on a single stock, you could miss other opportunities that better match your goals, risk comfort, or income needs across the market.

• Target potential mispricing by scanning a focused set of screener containing 21 high quality undiscovered gems that many investors may not be watching yet.
• Strengthen your portfolio’s foundation by reviewing companies in the solid balance sheet and fundamentals stocks screener (46 results) that pair financial resilience with fundamental support.
• Build a clearer risk profile by comparing opportunities across the 65 resilient stocks with low risk scores so you are not only relying on high volatility stories.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.